Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Clinical trial NCT05097443 · UNKNOWN

Trial details

NCT number: NCT05097443
Sponsor: Shandong Provincial Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified Diffuse Large B-cell Lymphoma Mantle Cell Lymphoma B-cell NonHodgkin Lymphoma

Start date: 2021-04-15
Primary completion: 2023-12-31
Enrollment: 130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.